Is BridgeBio Pharma Inc (BBIO) overvalued? · rev $221.9M
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
This page asks whether BridgeBio Pharma Inc (BBIO) looks expensive on cached numbers — not a short thesis.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
BBIO currently screens at market cap $13.24B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BBIO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BBIO stock page for the full model, not this heading.
Not investment advice.